News

The financial pain from your healthcare cost is real, you are uniquely placed to negotiate prices down, and hospitals, at 46% of spending, are where to look, says the CEO and president of the Health Care Cost Institute, which issued its annual cost and utilization report today.

Spending on prescription drugs grew by 40%, faster than spending on inpatient care, outpatient care and professional services, according to a new report from the Health Care Cost Institute.

Meta-analysis links assisted reproduction tech (ART) to higher risks of major heart defects in pregnancies, urging targeted screening and long-term heart health follow-up.

A new Health Care Cost Instittue report finds prices, not utilization, drove spending growth in employer coverage from 2019 to 2023, echoing the group's very first report — and the title of Uwe Reinhardt's famous article.

Reading C-peptide alongside glucose could better predict which autoantibody-positive people will develop type 1 diabetes and detect treatment effects sooner.

Electronic health record developers, health plans, manufacturers and discount programs could support early prescribing decisions by enabling providers and patients to view more pricing options at the point of prescribing, says Joseph Kleiman, president of Buzz Health.

Fariha Abbasi-Feinberg, MD, discusses underdiagnosed sleep disorders, what a recent insomnia-stroke study does and doesn't prove, and where health plan policy still lags behind the evidence.

The Health Care Cost Institute’s annual healthcare cost and utilization report on healthcare spending by those with employer-based health insurance shows that price increases, not utilization, account for soaring cost increases. HCCI CEO Katie Martin says employers should focus on bringing down hospital prices.

An ophthalmic imaging specialist outlined how lighting technique and serial documentation help clinicians tell normal iris pigment from disease.

Topical steroids remain first-line for chronic hand eczema, but long-term use can thin the skin and leave patients with poorly controlled disease.

Laura Ferris urges risk-based melanoma screening and highlights earlier immunotherapy, selective imaging, vaccine limits and new post–PD-1 options.

Patients with HS should get three to four months on a biologic before a switch, says a dermatologist who sees promise in oral JAK inhibitors.

With three FDA-approved biologics for hidradenitis suppurativa, Jennifer Hsiao, M.D., said patient preference and access often decide which comes first.

A structured approach grounded in implementation science and supported by a culture that values continuous improvement can enable organizations to identify barriers, align stakeholders and sustain new practices over time.

New unattended sleep testing codes take effect Jan. 1, 2027 — but a dispute over how CMS values them could shape access to the cheaper alternative to in-lab sleep studies.

A session at AAO 2026 explained how Medicare, Medicare Advantage and commercial coverage policies differ in ophthalmology, and how practices can document and code to stay compliant

Presenters at AAO 2026 examined hospital eye coverage gaps, workforce strain and how ophthalmology can gain influence within health systems.

Price transparency data on 11 glaucoma surgery codes showed payer class was most consistently tied to price, with Medicaid and self-pay rates lowest.

Experts at Fall Clinical Derm 2026 urge early JAK inhibitors over systemic steroids for atopic dermatitis and long-term vitiligo treatment, saying boxed-warning risks are overstated.

Art Papier, M.D., CEO of VisualDx, says darker skin tones have been underrepresented in dermatology resources for decades and explains how his company works backward from known diagnostic errors.

The 2026 American Academy of Ophthalmology Meeting got started today in New Orleans with a mix of celebration and candor about the challenges facing ophthalmology today.

How LLM decision support reshapes dermatology care, helping non-specialists diagnose while navigating trust gaps, ambiguity, and hallucination risks at Fall Clinical Derm.

Real-world data at the 2026 Fall Clinical Dermatology Conference show dupilumab in children with atopic dermatitis cuts new allergies and asthma risk versus steroids.

Sagimet CEO David Happel shares insights on denifanstat, highlighting strong acne response, tolerability and optimism for a denifanstat U.S. trial.

Sagimet CEO David Happel says oral denifanstat could sharply cut antibiotic use in acne and be used before patients ever need isotretinoin.

GLP-1 drug spending surges and rewires diabetes care as session at teh 2026 PBMI Annual National Conference spotlight PBM disruption, AI-driven actionable data, and new state reporting rules.

Sagimet Biosciences’ denifanstat oral acne pill shows rapid, sustained lesion cuts and higher clear-skin rates in phase 3, offering an antibiotic-sparing option.

A number of pharmacy benefit managers are creating programs geared to the healthcare needs of women.